Finance3h agoAsianet Newsable

CAPR Stock Is Crashing Today – FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote

in5points

Capricor's stock CAPR is crashing after FDA briefing documents cast doubt on Deramiocel.
The FDA raised concerns over Deramiocel's effectiveness for cardiomyopathy in Duchenne muscular dystrophy patients.
The briefing documents were released ahead of a key vote on the therapy's approval.

3h ago · original ↗

Asianet Newsable

Center-right

Mixed factuality

Who owns this?

Asianet News Network

Rajeev Chandrasekhar / Jupiter Capital interests historically

Wikipedia: Rajeev Chandrasekhar

Coverage spectrum

Left blind spot

Only right-leaning outlets are covering this so far.

Outlet lean

1 source

-

Left

Center

Right

Compare headlines

Same story, different framing

CenterAsianet Newsable
CAPR Stock Is Crashing Today – FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote
The article frames the FDA briefing as casting doubt on Deramiocel's efficacy, focusing on the negative impact on Capricor's stock price.
RightAsianet Newsable
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document
The headline emphasizes Capricor's accusation against the FDA and the resulting stock drop, framing the story from a business and corporate perspective.

›

Also covered by

2 outlets